Cubist Systematic Strategies LLC Purchases 110,682 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Cubist Systematic Strategies LLC increased its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 49.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 334,632 shares of the company's stock after acquiring an additional 110,682 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.28% of 10x Genomics worth $4,805,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of TXG. Atria Wealth Solutions Inc. increased its stake in shares of 10x Genomics by 9.6% in the fourth quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after purchasing an additional 943 shares in the last quarter. Blue Trust Inc. grew its stake in 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after buying an additional 1,299 shares in the last quarter. Sound Income Strategies LLC grew its stake in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after buying an additional 1,330 shares in the last quarter. Signaturefd LLC grew its stake in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after buying an additional 1,452 shares in the last quarter. Finally, KBC Group NV grew its stake in 10x Genomics by 57.3% in the 4th quarter. KBC Group NV now owns 5,072 shares of the company's stock worth $73,000 after buying an additional 1,847 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

Insider Activity at 10x Genomics

In other news, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now owns 879,482 shares in the company, valued at $9,735,865.74. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. The trade was a 1.35% decrease in their position. The disclosure for this sale can be found here. 9.39% of the stock is currently owned by insiders.

10x Genomics Stock Performance

Shares of 10x Genomics stock traded down $0.05 during trading on Thursday, hitting $9.07. The company's stock had a trading volume of 1,105,922 shares, compared to its average volume of 2,346,670. The company has a fifty day simple moving average of $8.83 and a two-hundred day simple moving average of $12.45. The company has a market capitalization of $1.11 billion, a PE ratio of -5.97 and a beta of 1.94. 10x Genomics, Inc. has a 52 week low of $6.78 and a 52 week high of $27.49.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The company had revenue of $154.88 million for the quarter, compared to the consensus estimate of $131.91 million. During the same period in the prior year, the firm posted ($0.50) EPS. 10x Genomics's revenue for the quarter was down 2.3% on a year-over-year basis. As a group, analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TXG shares. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a research note on Monday. Leerink Partnrs cut shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. Barclays cut their price objective on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, May 10th. Finally, Leerink Partners cut shares of 10x Genomics from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $16.42.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.